- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.07. | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 129 | PR Newswire | SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under... ► Artikel lesen | |
| 14.07. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome | 176 | PR Newswire | -- ATR 1072 is the company's first precision cardiology program to enter the clinic --
-- Corventis will be the first clinical trial for people living with PRKAG2... ► Artikel lesen | |
| 15.05. | Leerink startet Coverage für Atrium Therapeutics mit "Outperform" | 2 | Investing.com Deutsch | ||
| 15.05. | Leerink initiates Atrium Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 15.05. | Atrium Therapeutics, Inc. reports Q1 results | 1 | Seeking Alpha | ||
| ATRIUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Atrium Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Atrium Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Atrium Therapeutics Reports First Quarter 2026 Financial Results | 601 | PR Newswire | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 23.04. | Kooperation mit Bristol Myers Squibb: Atrium Therapeutics sichert sich Meilensteinzahlung von 15 Mio. US-Dollar | 24 | Investing.com Deutsch | ||
| 23.04. | Atrium Therapeutics earns $15M from Bristol Myers Squibb | 5 | Investing.com | ||
| 23.04. | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | 401 | PR Newswire | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen | |
| 17.04. | Atrium Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 02.03. | Novartis spaltet Atrium Therapeutics aus Avidity-Übernahme ab | 30 | transkript.de | ||
| 01.03. | Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions | 7 | MedCity News | ||
| 27.02. | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | 8 | BioPharma Dive | ||
| 27.02. | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | 6 | FierceBiotech | ||
| 27.02. | Atrium Therapeutics Launches with $270M | 2 | Contract Pharma | ||
| 27.02. | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | 834 | PR Newswire | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| 26.02. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,525 | -2,09 % | Chancen & Risiken bei den Q.2-Kennzahlen - Almonty Industries, BioNTech, Danaher, Pfizer, Sartorius | Die globalen Aktienmärkte bleiben dynamisch, und die fundamentalen Rahmenbedingungen haben sich in den letzten Quartalen rasant verändert. Im heutigen Bericht analysieren wir drei faszinierende Unternehmen... ► Artikel lesen | |
| GILEAD SCIENCES | 112,66 | -2,85 % | Gileads nächste Milliardenwette rückt näher: Nach HIV jetzt HSV? | Seit Jahren dominiert Gilead Sciences die Virologie vor allem mit seinem milliardenschweren HIV-Geschäft. Doch hinter den Kulissen scheint der US-Pharmariese längst an der nächsten großen Franchise... ► Artikel lesen | |
| AURORA CANNABIS | 2,440 | +2,52 % | Aurora Cannabis Inc (3): Aurora gets ISS backing ahead of annual meeting vote | ||
| TEVA | 30,300 | -0,33 % | Medincell: UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | Regulatory News:
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached a record $77 million in Q2 2026, up 43%... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 409,30 | -3,07 % | AbCellera, Vertex partner on next-gen T-cell engagers | ||
| VIATRIS | 15,304 | -1,82 % | Viatris Inc.: Viatris Receives U.S. FDA Approval for Gwyn Lo, a Once-Weekly Contraceptive Patch | New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option
Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health
... ► Artikel lesen | |
| EYEPOINT | 10,700 | +2,88 % | EyePoint, Inc.: EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) | - COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients --... ► Artikel lesen | |
| BAUSCH HEALTH | 5,230 | +27,81 % | Bausch Health Companies Inc.: Bausch Health Announces Second Quarter 2026 Results, Raises Guidance | Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period
GAAP Net... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 45,890 | -2,78 % | H.C. Wainwright lowers Ionis Pharmaceuticals price target to $115 | ||
| ASSEMBLY BIOSCIENCES | 22,600 | +3,20 % | Assembly Biosciences: Der wichtigste HSV-Moment der Biotech-Geschichte steht bevor | Während sich die Biotech-Welt seit Jahren auf Themen wie Adipositas, neuartige Krebstherapien und künstliche Intelligenz fokussiert, könnte sich im Hintergrund eine der größten unentdeckten Chancen... ► Artikel lesen | |
| BIONANO GENOMICS | 1,050 | -3,67 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 61,96 | +3,40 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| ALNYLAM PHARMACEUTICALS | 175,05 | -30,29 % | Alnylam Pharma Reports Net Income In Q2; Revises 2026 TTR Net Product Revenue Guidance | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported second quarter net income of $164.5 million, compared to a net loss of $72.2 million a year ago. Profit per share totaled... ► Artikel lesen | |
| AMARIN | 12,000 | -3,23 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,789 | +2,33 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen |
Das Unternehmen ATRIUM THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-0,87 %) liegt der Kurs bei 11,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATRIUM THERAPEUTICS INC finden Sie auf Wallstreet Online.